The Futurist's Dilemma – Can We Enable Clinical Trials Operations Without Human-In-The-Loop?

As the complexity and costs of clinical trials rise, the biopharma sector aims to boost efficiency and precision in clinical operations. Experts are promoting the adoption of technological innovations and Generative AI (GenAI) to transform drug development, striving for an environment that reduces human error and resource limitations while maintaining continuous productivity. This evolution prompts a critical examination of human oversight in trials—whether it should be redefined or eliminated due to potential risks.

This forthcoming webinar featuring prominent industry leaders will explore these pivotal topics, focusing on the prerequisites for a fully autonomous clinical operations model, including advancements in technology, infrastructure, and regulation. The panel will evaluate both the benefits and dangers associated with heightened automation in clinical trials, advocating for a reassessment of conventional practices and the pursuit of novel risk management strategies. The goal is to envision a future characterized by faster and more efficient clinical trials.